中华放射肿瘤学杂志
Monday, Apr. 7, 2025   Home | Journal | Editorial | Instruction | Subscription | Advertisement | Academic | Index-in | Contact Us | Chinese
Chinese Journal of Radiation Oncology  2018, Vol. 27 Issue (12): 1066-1071    DOI: 10.3760/cma.j.issn.1004-4221.2018.12.007
Abdominal Tumors Current Issue| Next Issue| Archive| Adv Search [an error occurred while processing this directive] | [an error occurred while processing this directive]
Clinical efficacy and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced low and middle rectal cancer
Liu Yan, Lyu Yin, Lu Yanrong, Xiao Nan, Wu Wanyan, Zhang Jinrong
Department of Thoracic and Abdominal Radiotherapy,the Third Clinical Medical College of Xinjiang Medical University (the Affiliated Cancer Hospital),Urumqi 830011,Xinjiang,China
Download: PDF (0 KB)   HTML (1 KB) 
Export: BibTeX | EndNote (RIS)      Supporting Info
Abstract  Objective To investigate the clinical efficacy of neoadjuvant chemoradiotherapy in the treatment of locally advanced low and middle rectal cancer,and evaluate the effect of related clinical factors upon the long-term survival. Methods Clinical data of 101 patients with locally advanced low and middle rectal cancer admitted to our hospital from January 1,2010 to December 31,2014 were collected. All patients completed the preoperative intensity-modulated radiation therapy DT45-50.4 Gy,synchronized with oxaliplatin+capecitabine/5-fluorouracil or single drug capecitabine chemotherapy,and total mesorectal excision) was performed 4-13 weeks after the end of the neoadjuvant therapy. The short-term efficacy and long-term prognosis of these patients were evaluated. Kaplan-Meier method was used for survival analysis,and Cox’s regression model for multivariate analysis. Results The total sphincter preservation rate was 53.5%.The decrease rates of T,N staging and TNM total staging were 73.26%,67.32% and 72.3%,respectively. The pathological complete response (pCR) rate was 16.8%.The median follow-up time was 41 months. The 3-year overall survival (OS), desease-free survival (DFS),local recurrence and distant metastases rates were 82.2%,80.7%,7.2% and 12.1%,respectively. The single factor analysis demonstrated that ypT and ypN stages were the risk factors affecting the 3-year OS,DFS anddistant metastases (all P<0.05).Multivariate analysis revealed that ypT stage was an independent factor affecting the 3-year OS,and ypT and ypN stages were the independent factors of the 3-year DFS (all P<0.05). Conclusions Neoadjuvant chemoradiotherapy combined with TME in the treatment of locally advanced middle and low rectal cancer can partially decrease the tumor staging,enhance the sphincter preservation rate and improve long-term clinical prognosis. Both ypT and ypN stages are correlated with the clinical prognosis of patients.
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
Liu Yan
Lyu Yin
Lu Yanrong
Xiao Nan
Wu Wanyan
Zhang Jinrong
Key wordsRectal neoplasms/chemoradiotherapy      Prognosis     
Received: 19 June 2018     
Fund:Natural Science Foundation of the Xinjiang Uygur Autonomous Region (2016D01C361)
Corresponding Authors: Zhang Jinrong,Email:zjr8043@163.com   
Cite this article:   
Liu Yan,Lyu Yin,Lu Yanrong et al. Clinical efficacy and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced low and middle rectal cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1066-1071.
Liu Yan,Lyu Yin,Lu Yanrong et al. Clinical efficacy and prognostic factors of neoadjuvant chemoradiotherapy for locally advanced low and middle rectal cancer[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1066-1071.
URL:  
http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.12.007     OR     http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I12/1066
  Copyright © 2010 Editorial By Chinese Journal of Radiation Oncology
Support by Beijing Magtech Co.ltd  support@magtech.com.cn